<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04736355</url>
  </required_header>
  <id_info>
    <org_study_id>201800387A3</org_study_id>
    <nct_id>NCT04736355</nct_id>
  </id_info>
  <brief_title>DAOIB for the Treatment of Mild Cognitive Impairment</brief_title>
  <official_title>DAOIB for the Treatment of Mild Cognitive Impairment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chang Gung Memorial Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chang Gung Memorial Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      NMDA neurotransmission plays an important role in learning and memory. NMDA&#xD;
      receptor-enhancing agent improved the cognitive function of patients with early-phase&#xD;
      Alzheimer's disease. This study is a randomized, double-blind, placebo-controlled drug trial.&#xD;
      All subjects will be allocated randomly to 2 groups: (1) DAOIB group; (2) placebo group. The&#xD;
      study period is 24 weeks. The investigators hypothesize that DAOIB may yield better efficacy&#xD;
      than placebo for cognitive function in patients with mild cognitive impairment.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 1, 2020</start_date>
  <completion_date type="Anticipated">December 2022</completion_date>
  <primary_completion_date type="Anticipated">December 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline in the Alzheimer's disease assessment scale - cognitive subscale at week 8, 16 and 24</measure>
    <time_frame>week 0, 8, 16, 24</time_frame>
    <description>Alzheimer's disease assessment scale-cognitive subscale consists of 11 tasks. Its scores range from 0 (best) to 70 (worst).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in Clinician's Interview-Based Impression of Change plus Caregiver Input score at week 8, 16 and 24</measure>
    <time_frame>week 8, 16, 24</time_frame>
    <description>Clinician's Interview-Based Impression of Change plus Caregiver Input score is a global assessment of change based on a comprehensive, semi-structured interview which includes caregiver-supplied information. It is a 7-point rating scale ranging from 1-7, where 1 represents markedly improved; 4, no change; and 7, markedly worse.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in Alzheimer's disease Cooperative Study scale for ADL in MCI (ADCS-MCI-ADL) score at week 8, 16 and 24</measure>
    <time_frame>week 0, 8, 16, 24</time_frame>
    <description>ADCS-MCI-ADL appears to be a suitable instrument for evaluating activities of daily living in mild cognitive impairment. Its scores range from 0 (worst) to 78 (best).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in Medical Outcomes Study Short-Form-36 (SF-36) score at week 8, 16 and 24</measure>
    <time_frame>week 0, 8, 16, 24</time_frame>
    <description>The SF-36 consists of eight sections which assess the quality of life.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in the composite score of a battery of additional cognitive tests at week 8, 16 and 24</measure>
    <time_frame>week 0, 24</time_frame>
    <description>The battery of additional cognitive tests include speed of processing (Category Fluency), working memory (verbal and nonverbal, Wechsler Memory Scale), learning and memory tests (verbal and visual, Wechsler Memory Scale)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Mild Cognitive Impairment</condition>
  <arm_group>
    <arm_group_label>DAOIB</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>oral, for 24 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>oral, for 24 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DAOIB</intervention_name>
    <description>oral, for 24 weeks</description>
    <arm_group_label>DAOIB</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>oral, for 24 weeks</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Clinical diagnosis of mild cognitive impairment&#xD;
&#xD;
          -  MMSE between 17-26&#xD;
&#xD;
          -  CDR 0.5&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Hachinski Ischemic Score &gt; 4&#xD;
&#xD;
          -  Substance abuse/dependence&#xD;
&#xD;
          -  Parkinson disease, epilepsy, dementia with psychotic features&#xD;
&#xD;
          -  Major psychiatric disorders&#xD;
&#xD;
          -  Major physical illnesses&#xD;
&#xD;
          -  Severe visual or hearing impairment&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Chang Gung Memorial Hospital</name>
      <address>
        <city>Kaohsiung</city>
        <zip>886</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chieh-Hsin Lin, MD, PhD</last_name>
      <phone>886-7-7317123</phone>
      <phone_ext>8753</phone_ext>
      <email>cyndi36@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Chieh-Hsin Lin, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>January 31, 2021</study_first_submitted>
  <study_first_submitted_qc>January 31, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 3, 2021</study_first_posted>
  <last_update_submitted>January 31, 2021</last_update_submitted>
  <last_update_submitted_qc>January 31, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 3, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cognitive Dysfunction</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

